

National Institute for Health and Care Excellence

IP1090 Bioresorbable stent implantation for treating coronary artery disease

IPAC date: 9 June 2022

Com. no.	Consultee name and organisation	Sec. no.	Comments	Response
1	<p>Consultee 1 NHS professional On behalf of BCIS, Clinical Standards Group.</p>	1	<p>NICE have updated guidance from 2014 on treatment of coronary disease with bioabsorbable stents. (BRS) https://www.nice.org.uk/guidance/ipg492</p> <p>They considered evidence from 1 HTA, 1 RCT, 3 systematic, reviews with meta-analysis, 5 case series and 2 case reports. 31,605 patients had BRS. There was some overlap of studies included in the published overviews.</p> <p>There was no evidence that BRS had better results than DES in any of the studies.</p> <p>NICE recommend that BRS are only implanted in patients in the context of research.</p> <p>They also recommend that details of patients and procedures using BRS are included in the NICOR database of PCI.</p> <p>They recommend that future research should include randomised controlled trials reporting details of patient selection and choice of bioresorbable stent. It should also include long-term outcomes.</p> <p>Comments</p> <p>Comprehensive data review with no results to suggest superior outcomes from BRS vs DES, and significant safety concerns. Absolute differences are small.</p> <p>We support the conclusion that BRS implantation should be restricted to patients recruited to research protocols."</p>	<p>Please respond to all comments</p> <p>Thank you for your comments and supporting the recommendations in the guidance.</p>

"Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees."